<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30092967</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1876-7591</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>11</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>JACC. Cardiovascular imaging</Title>                <ISOAbbreviation>JACC Cardiovasc Imaging</ISOAbbreviation>            </Journal>            <ArticleTitle>Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.</ArticleTitle>            <Pagination>                <MedlinePgn>1084-1093</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1936-878X(18)30527-8</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcmg.2018.06.005</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study sought to determine the rate of chemotherapy-related cardiotoxicity and to estimate adherence to recommendations for cardiac monitoring among breast cancer patients treated with chemotherapy.</AbstractText>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Heart failure (HF) is a known complication associated with cancer therapies. Little is known regarding the rate of chemotherapy-related cardiotoxicity and adherence to recommendations for cardiac monitoring among chemotherapy-treated breast cancer patients.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients &gt;18 years of age with a diagnosis of nonmetastatic invasive breast cancer between 2009 and 2014, treated with chemotherapy within 6 months of their diagnosis, were identified in the Truven Health MarketScan (IBM Watson Health, Cambridge, Massachusetts) database. HF, comorbidities, and treatment details were identified using diagnosis and billing codes. Analyses included descriptive statistics, Cox proportional hazard regression, and logistic regression.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 16,456 patients were included; the median age was 56 years old. Cardiotoxicity was identified in 4.2% of patients. Therapy with trastuzumab (hazard ratio [HR]: 2.01; 95% confidence interval [CI]: 1.72 to 2.36) and anthracyclines (HR: 1.53; 95% CI: 1.30 to 1.80), Deyo comorbidity scores (HR: 1.38; 95% CI: 1.15 to 1.66; HR: 2.47; 95% CI: 1.94 to 3.15 for scores of 1 and ≥2, respectively), hypertension (HR: 1.28, 95% CI: 1.09 to 1.51), and valve disease (HR: 1.93; 95% CI: 1.48 to 2.51) were associated with an increased risk of cardiotoxicity. Patients ≤35 years of age (HR: 0.37; 95% CI: 0.19 to 0.72) and 36 to 49 years of age (HR: 0.49; 95% CI: 0.38 to 0.62) were less likely to have cardiotoxicity than patients 65 years of age and older. Among 4,325 patients treated with trastuzumab, guideline-adherent cardiac monitoring was identified in 46.2% of patients. Therapies using anthracyclines (odds ratio [OR]: 1.58; 95% CI: 1.35 to 1.87), taxanes (OR: 1.63; 95% CI: 1.27 to 2.08), and radiation (OR: 1.22; 95% CI: 1.08 to 1.39) were associated with guideline-adherent monitoring.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HF is an uncommon complication of breast cancer therapies. The risk was higher among patients treated with trastuzumab or anthracyclines and lower in younger patients. Cardiac monitoring among trastuzumab-treated patients should be a priority among high-risk patients and in the presence of comorbidities or other chemotherapies such as those using anthracyclines.</AbstractText>                <CopyrightInformation>Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Henry</LastName>                    <ForeName>Mariana L</ForeName>                    <Initials>ML</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Niu</LastName>                    <ForeName>Jiangong</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Ning</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giordano</LastName>                    <ForeName>Sharon H</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chavez-MacGregor</LastName>                    <ForeName>Mariana</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: MChavez1@mdanderson.org.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P30 CA016672</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>JACC Cardiovasc Imaging</MedlineTA>            <NlmUniqueID>101467978</NlmUniqueID>            <ISSNLinking>1876-7591</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2009 Mar 10;100(5):684-92</RefSource>                <PMID Version="1">19259090</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Nov 1;30(31):3792-9</RefSource>                <PMID Version="1">22987084</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epidemiology. 2016 Jan;27(1):6-13</RefSource>                <PMID Version="1">26414938</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2012 Dec 18;60(24):2504-12</RefSource>                <PMID Version="1">23158536</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Breast Cancer. 2014 Dec;17(4):363-9</RefSource>                <PMID Version="1">25548585</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Jul 1;33(19):2176-83</RefSource>                <PMID Version="1">25964256</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Card Fail. 2012 Feb;18(2):113-9</RefSource>                <PMID Version="1">22300778</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Jul 20;28(21):3407-10</RefSource>                <PMID Version="1">20530269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603</RefSource>                <PMID Version="1">22744937</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Apr 1;34(10):1030-3</RefSource>                <PMID Version="1">26834055</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CMAJ Open. 2016 Feb 18;4(1):E66-72</RefSource>                <PMID Version="1">27280116</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Oncol. 2016 Jan;2(1):29-36</RefSource>                <PMID Version="1">26539793</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2013 Aug;22(4):482-7</RefSource>                <PMID Version="1">23664254</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Heart Assoc. 2014 Feb 28;3(1):e000472</RefSource>                <PMID Version="1">24584736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Sep 1;28(25):3910-6</RefSource>                <PMID Version="1">20679614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Contemp Oncol (Pozn). 2013;17(2):190-5</RefSource>                <PMID Version="1">23788989</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Manag Care. 2014;20(1):86-92</RefSource>                <PMID Version="1">24512167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2008 Jan 1;14(1):14-24</RefSource>                <PMID Version="1">18172247</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Epidemiol. 1992 Jun;45(6):613-9</RefSource>                <PMID Version="1">1607900</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Sep 10;34(26):3157-65</RefSource>                <PMID Version="1">27458291</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2011 Jul-Aug;17(4):383-90</RefSource>                <PMID Version="1">21615821</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Jul 1;34(19):2239-46</RefSource>                <PMID Version="1">27091709</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2016 May;21(5):555-62</RefSource>                <PMID Version="1">27009939</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 20;31(33):4222-8</RefSource>                <PMID Version="1">24127446</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Mar 10;26(8):1231-8</RefSource>                <PMID Version="1">18250349</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">cardiac monitoring</Keyword>            <Keyword MajorTopicYN="N">cardio-oncology</Keyword>            <Keyword MajorTopicYN="N">cardiotoxicity</Keyword>            <Keyword MajorTopicYN="N">trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30092967</ArticleId>            <ArticleId IdType="pii">S1936-878X(18)30527-8</ArticleId>            <ArticleId IdType="doi">10.1016/j.jcmg.2018.06.005</ArticleId>            <ArticleId IdType="pmc">PMC6149535</ArticleId>            <ArticleId IdType="mid">NIHMS987403</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>